GRTX News and Press, Galera Therapeutics Inc. From 09/01/22

Biopharmaceutical company Galera Therapeutics ( NASDAQ: GRTX ) appointed Eugene Kennedy chief medical officer. Kennedy, who has served as chief medical officer at Innovative Cellular Therapeutics, will succeed Jon Holmlund. Holmlund will retire at 2022-end, a...

MALVERN, Pa., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today an...

Galera Therapeutics press release ( NASDAQ: GRTX ): Q2 GAAP EPS of -$0.54. As of June 30, 2022, Galera had cash, cash equivalents and short-term investments of $52.0 million. Galera expects that its existing cash, cash equivalents and short-term investments will enable Gal...

Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 Phase 3 ROMAN trial data highlighted in an oral presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Phase 1 stage of GRECO-1 trial demonstrated rucosopasem in combin...

Galera Therapeutics ( NASDAQ: GRTX ) stock has lost 7.8% to $1.42 in Wednesday morning trade after announcing phase 1 data for its molecule rucosopasem in combination with stereotactic body radiation therapy to treat patients with non-small cell lung cancer. The result...

Rucosopasem was safe and well tolerated Early indications of anti-cancer activity and pulmonary function preservation Enrollment ongoing in the randomized, double-blinded, placebo-controlled Phase 2 stage of this trial MALVERN, Pa., June 29, 2022 (GLOBE NEWSWIRE) -...

MALVERN, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today ann...

Avasopasem produced clinically meaningful, statistically significant reduction of severe oral mucositis (SOM) in patients with locally advanced head and neck cancer receiving radiotherapy Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 MALVERN, Pa....

Galera Therapeutics press release (NASDAQ:GRTX): Q1 GAAP EPS of -$0.58. Cash and cash equivalents of $60.95M For further details see: Galera Therapeutics GAAP EPS of -$0.58

Galera Therapeutics (NASDAQ:GRTX) said it intends to file a new drug application (NDA) with the U.S. Food and Drug Administration (FDA) by the end of 2022 for avasopasem manganese (avasopasem) to treat radiotherapy-induced severe oral mucositis (SOM) in patients with locally advanced hea...